Minerva Neurosciences, Inc. NERV
2.35 USD 0.00 (+0.21%)
At closeNov 3, 2026, 4:01 PM EST
2.35 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
2.29 Day range 2.48
1.96 52-week range 8.80
- YTD
- -41.54%
- 1 year
- -38.48%
- Market cap
- 112.21M
- EPS (ttm)
- -36.12
- Shares out
- 6.99M
- Forward P/E
- -0.79
- YTD return
- -41.54%
- 1-year return
- -38.48%
- Volume
- 240.55K
- Avg volume
- 189.88K
- Open
- 2.37
- Previous close
- 2.35
- Day's range
- 2.29 – 2.48
- 52-week range
- 1.96 – 8.80
- Beta
- 0.17
- Price target
- 5.00 (+112.8%)
2Y +0.01 (+0.43%)
Key statistics
- Enterprise value
- 48.58M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.77M
- Total cash
- 26.53M
- Total debt
- 60.00M
- Return on equity
- 0.00%
- Short % of float
- 0.23%
- 50-day average
- 2.33
- 200-day average
- 2.67
Analyst view
Price target (mean) 5.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.05.
Financials — quick view
NERV Revenue — quarterly 0
NERV Net income — quarterly 17.47M
NERV EPS — quarterly 0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -1.01 | 2.97 | +3.98 | +394.06% |
| Aug 6, 2024 | Jun 1, 2024 | -0.97 | -1.09 | -0.12 | -12.37% |
| May 1, 2024 | Mar 1, 2024 | -1.20 | -1.13 | +0.07 | +5.83% |
| Feb 22, 2024 | Dec 1, 2023 | -0.88 | -1.19 | -0.31 | -35.23% |
| Nov 7, 2023 | Sep 1, 2023 | -0.77 | -1.03 | -0.26 | -33.77% |
| Aug 1, 2023 | Jun 1, 2023 | -0.44 | -1.12 | -0.68 | -154.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 7, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| May 2, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Feb 27, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 2, 2023 | HC Wainwright & Co. | main | Neutral | Neutral |
| May 16, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- minervaneurosciences.com
News
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London 
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia 
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences 
Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50 
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10 
Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate 
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates 
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs 
CORRECTION: Minerva Neurosciences Establishes $75M At-The-Market Stock Offering Program With Leerink Partners
Your note
Sign in to keep a note on NERV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AHLHOLM FREDERICK W | Chief Financial Officer | Sale | Apr 30, 2023 | 17,518 |
| LUTHRINGER REMY | Chief Executive Officer | Sale | May 1, 2023 | 184,819 |
| RACE GEOFFREY | President | Sale | Apr 30, 2023 | 51,324 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 19.32% | 1,351,275 | 2.86M | Sep 29, 2024 |
| Vanguard Group Inc | 3.60% | 252,060 | 534.37K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.25% | 157,200 | 333.26K | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 1.53% | 107,256 | 227.38K | Sep 29, 2024 |
| Blackrock Inc. | 1.04% | 72,669 | 154.06K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 56,456 | 119.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 11.91% | 833,000 | 1.77M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 9.95% | 696,150 | 1.48M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.51% | 175,805 | 372.71K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.06% | 74,257 | 157.42K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 30,073 | 63.75K | Oct 30, 2024 |
| Federated Hermes Kaufmann Fund II | 0.25% | 17,225 | 36.52K | Sep 29, 2024 |